Men with newly diagnosed non-metastatic prostate cancer who were randomly assigned to surgery, radiation, or active monitoring had similar overall and prostate cancer-specific survival rates after 15 years.
This lab is helping fight the STI testing shortage caused by COVID-19
Share Article
MicroGenDX is a PCR and NGS lab with its own lab developed test (LDT) and is not impacted by the same shortages that are causing delays in STI testing elsewhere.
MicroGenDX Logo
MicroGenDX has over 11 years’ experience designing, and validating laboratory developed tests and mitigating risk in supply chains so that we are able to run the test you need when you need it. ORLANDO, Fla. (PRWEB) December 21, 2020 In an era when shortages abound, having options is invaluable. Worldwide, labs are facing a scarcity of supplies, as those needed to test for diseases such as sexually transmitted infections (STIs) must be diverted to Covid-19 testing. Enter MicroGenDX, a company specializing in qPCR + Next Generation Sequencing (NGS) microbial molecular diagnostics.a company that designs and set up its own tests and multiplex panels in-ho